StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $3.97 | $3.98 | +0.25% | 0.0M |
| 05-13 | $3.95 | $3.95 | +0.00% | 0.0M |
| 05-14 | $3.91 | $3.96 | +1.28% | 0.0M |
| 05-15 | $3.88 | $4.00 | +3.09% | 0.0M |
| 05-18 | $3.97 | $4.00 | +0.76% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
| Metric | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $2.57M | $7.14M | $5.68M | $3.13M |
Operating Income | $-4.35M | $-28.11M | $-17.30M | $-11.63M |
Net Income | $-9.58M | $-29.40M | $-16.69M | $-6.97M |
EPS (Diluted) | $-3.72 | $-11.42 | $-6.48 | $-4.34 |
Total Assets | $38.95M | $35.20M | $51.33M | $72.50M |
Total Liabilities | $47.02M | $40.83M | $50.62M | $60.90M |
Cash & Equivalents | $34.22M | $31.61M | $37.06M | $49.24M |
Free Cash Flow OCF − CapEx | Not available | $-19.35M | $-14.52M | $-7.86M |
Shares Outstanding | 1.52M | 2.57M | 54.85M | 54.84M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.